The incidence and prevalence of primary biliary cholangitis are reportedly growing. As a result, the market for primary biliary cholangitis treatments is expected to expand, with some forecasts suggesting it will reach significant value by 2033 or gain momentum through 2034. Research into the condition and its treatments is ongoing, with studies examining its pathogenesis, management, and clinical characteristics, as well as the development of new treatments.